Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720156 | 1.00 | PPARG (0.62) | PPARGMAPTHPGDALDH1A1NPC1 | |
| SCHEMBL1719740 | 0.88 | PPARG (0.78) | PPARGMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL1719739 | 0.88 | PPARG (0.78) | PPARGMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL2229647 | 0.85 | LNPEP (0.60) | RAB9AGAATSHRLNPEPMDM4 | |
| SCHEMBL1720636 | 0.85 | PPARG (0.63) | PPARGMAPTHPGDHTT | |
| SCHEMBL1720634 | 0.85 | PPARG (0.63) | PPARGMAPTHPGDHTT | |
| SCHEMBL1720144 | 0.81 | PPARG (0.62) | PPARGHPGDALDH1A1KDM4ETSHR | |
| SCHEMBL1720146 | 0.81 | PPARG (0.62) | PPARGHPGDALDH1A1KDM4ETSHR | |
| SCHEMBL8722708 | 0.77 | GRIA1 (0.56) | MAPTHPGDALDH1A1NPC1RAB9A | |
| SCHEMBL8722398 | 0.77 | GRIA1 (0.56) | MAPTHPGDALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569904-B1 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) | 2012-01-11 | — | — | EP | disclosed |
| US-20080051321-A1 | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | LU XIAN-PING | 2008-02-28 | — | — | US | disclosed |
| US-7268157-B2 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-09-11 | — | — | US | disclosed |
| US-20040142921-A1 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142921-A1 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | PPARG 2/4885MAPT 4625/4885HPGD 3222/4885 |
| US-20080051321-A1 | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | PPARG 2/4885MAPT 4673/4885HPGD 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.